Immunomodulating functions of human leukocyte antigen-G and its role in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Bu, Xiaoyin; Zhong, Jinman; Li, Weiru; Cai, Shengchun; Gao, Ya; Ping, Baohong

doi:10.1007/s00277-021-04486-z

Cited by 10 publications

(8 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HLA-G does not seem to initiate immune responses as its classical homologues. In addition, a number of studies have highlighted the important role of this immune checkpoint molecule in the modulation of the immune system in immune-related diseases, tumors, and infections through the structure and dynamics of the different HLA-G isoforms [ 8 , 9 , 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

Immunomodulatory Potential of Non-Classical HLA-G in Infections including COVID-19 and Parasitic Diseases

et al. 2022

View full text Add to dashboard Cite

Human Leukocyte Antigen-G (HLA-G), a polymorphic non-classical HLA (HLA-Ib) with immune-regulatory properties in cancers and infectious diseases, presents both membrane-bound and soluble (sHLA-G) isoforms. Polymorphism has implications in host responses to pathogen infections and in pathogenesis. Differential expression patterns of HLA-G/sHLA-G or its polymorphism seem to be related to different pathological conditions, potentially acting as a disease progression biomarker. Pathogen antigens might be involved in the regulation of both membrane-bound and sHLA-G levels and impact immune responses during co-infections. The upregulation of HLA-G in viral and bacterial infections induce tolerance to infection. Recently, sHLA-G was found useful to identify the prognosis of Coronavirus disease 2019 (COVID-19) among patients and it was observed that the high levels of sHLA-G are associated with worse prognosis. The use of pathogens, such as Plasmodium falciparum, as immune modulators for other infections could be extended for the modulation of membrane-bound HLA-G in COVID-19-infected tissues. Overall, such information might open new avenues concerning the effect of some pathogens such as parasites in decreasing the expression level of HLA-G to restrict pathogenesis in some infections or to influence the immune responses after vaccination among others.

show abstract

Section: Introductionmentioning

confidence: 99%

Immunomodulatory Potential of Non-Classical HLA-G in Infections including COVID-19 and Parasitic Diseases

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The study by Boukouaci et al further demonstrated that HLA-G is induced in vivo during allogeneic transplantation leading to immune tolerance and reducing the risk of transplant rejection and GVHD (13). In ex vivo study, HLA-G expression on the surface of CD4 + T cells inhibits the proliferation of allogeneic-specific T cells when mixing with the allogenic lymphocytes (14). These studies indicate that HLA-G is highly related to immune reaction and tolerance.…”

Section: Introductionmentioning

confidence: 79%

The association between genetic variants at 3’-UTR and 5’-URR of HLA-G gene and the clinical outcomes of patients with leukemia receiving hematopoietic stem cell transplantation

Chen

Wang²,

Hour³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

In addition to the classical human leukocyte antigen (HLA) genes, the outcomes of post-hematopoietic stem cell transplantation (HSCT) are associated with human leukocyte antigen (HLA)-related genes and non-HLA genes involved in immune regulation. HLA-G gene plays an important role in immune tolerance, assisting immune escape of tumor cells, and decrease of transplant rejection. In this study, we explored the association of genetic variants at the 3’-untranslated region (3’-UTR) and 5’-upstream regulatory region (5’-URR) of HLA-G gene with the adverse outcomes of patients with leukemia receiving HSCT. The genomic DNAs of 164 patients who had acute leukemia and received HSCT were collected for analysis. Nine single nucleotide polymorphisms (SNPs) and six haplotypes in the 3’-UTR and 27 SNPs and 6 haplotypes in the 5’-URR were selected to investigate their relationship with the development of adverse outcomes for patients receiving HSCT, including mortality, relapse, and graft-versus-host disease. Our results revealed that two SNPs (rs371194629 and rs9380142) and one haplotype (UTR-3) located in the 3’-UTR and two SNPs (rs3823321 and rs1736934) and one haplotype (G0104a) located in the 5’-URR of HLA-G were associated with the occurrence of chronic GVHD or development of any forms of GVHD. No SNP was found to associate with the occurrence of mortality and relapse for patients receiving HSCT. These SNPs and haplotypes may play important roles in regulating immune tolerance of allografts post-HSCT that can be used to predict the risk of poor outcomes after receiving HSCT and giving preventive treatment to patients on time.

show abstract

“…It has also been described that HLA-G can induce the production of tolerant DCs. These molecules can also interact with other immune cells including NK cells, by binding to their inhibitory receptors [60] .…”

Section: Mscs: Towards Reducing the Immune Over-activation And Inflam...mentioning

confidence: 99%

Clinical progress in MSC-based therapies for the management of severe COVID-19

Rossello-Gelabert

Gonzalez‐Pujana

Igartúa

et al. 2022

Cytokine & Growth Factor Reviews

View full text Add to dashboard Cite

Immunomodulating functions of human leukocyte antigen-G and its role in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Cited by 10 publications

References 69 publications

Immunomodulatory Potential of Non-Classical HLA-G in Infections including COVID-19 and Parasitic Diseases

Immunomodulatory Potential of Non-Classical HLA-G in Infections including COVID-19 and Parasitic Diseases

The association between genetic variants at 3’-UTR and 5’-URR of HLA-G gene and the clinical outcomes of patients with leukemia receiving hematopoietic stem cell transplantation

Clinical progress in MSC-based therapies for the management of severe COVID-19

Contact Info

Product

Resources

About